Finansia Securities expects the medical group's normalised profit in the second quarter of 2026 to total 6.01 billion baht, down 8% from the previous quarter and down 2% from a year earlier, mainly due to slowing domestic spending and unrest in the Middle East affecting revenue from Thai and foreign patients. However, PR9's normalised profit stands out, growing 4% from the previous quarter and 5% from a year earlier, thanks to its ability to maintain revenue and control costs. Meanwhile, CHG's normalised profit is expected to grow 8% from a year earlier, the highest in the group, driven by company-specific positive factors. The research team maintains a positive view on the third quarter of 2026, expecting normalised profit to grow both quarter-on-quarter and year-on-year, supported by the seasonal high season, and continues to pick PR9 as the top stock in the group, given its accelerating profit trend from strategies to increase revenue from foreign patients and complex disease treatments.
Praram 9 Hospital Public Company LimitedPR9's normalised profit stands out, growing 4% QoQ and 5% YoY, due to maintaining revenue and controlling costs, and is top pick.
Chularat Hospital Public Company LimitedCHG's normalised profit expected to grow 8% year-on-year, highest in group, driven by company-specific positive factors.
